MHRA-100303-PIP01-21-M01 (update)

Key Facts

PIPS Key Facts
Active Substance
  • DARUNAVIR
  • COBICISTAT
  • EMTRICITABINE
  • TENOFOVIR ALAFENAMIDE
Invented Name
  • Symtuza
  • Symtuza
  • Symtuza
  • Symtuza
PIP Number MHRA-100303-PIP01-21-M01 (update)
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Film-coated tablet
Therapeutic area
Therapeutic area:
  • Infectious diseases
Conditions / Indications
Conditions / Indications:
  • Treatment of human immunodeficiency virus type-1 (HIV-1) infection
Route(s) of administration
Route(s) of administration:
  • Oral use
PIP applicant
Decision Type
Decision Type
PM: decision on the application for modification of an agreed paediatric investigation plan.
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

PIPS Decision Documents
Decision Document Decision Document on a Paediatric Investigation Plan (PIP):DARUNAVIR;COBICISTAT;EMTRICITABINE;TENOFOVIR ALAFENAMIDE.pdf
Published Date 29/07/2022